GLP-1s and Sleep Apnea: The First Drug Approved for OSA

Obstructive sleep apnea (OSA) is the repeated collapse of the upper airway during sleep, causing breathing to stop or become dangerously shallow for ten seconds or more at a time. Each event pulls you briefly out of deep sleep to reopen the airway — usually without you waking enough to remember it. Someone with severe OSA may have this happen thirty, fifty, or more times an hour, every hour, all night.

Severity is measured by the apnea-hypopnea index (AHI) — the average number of these events per hour of sleep. Under 5 is normal. Between 5 and 15 is mild, 15 to 30 moderate, and above 30 is severe. That single number is how sleep medicine grades the condition and how the SURMOUNT-OSA results are reported.

The consequences reach far past feeling tired. Untreated OSA is associated with hypertension, atrial fibrillation, stroke, type 2 diabetes, and cognitive impairment. Every apnea event triggers a surge of sympathetic nervous system activity and a drop in blood oxygen — a physiological stress response repeated hundreds of times a night for years.

Obesity is the dominant modifiable risk factor: fat deposition around the neck and pharynx narrows the airway, and reduced lung volume makes collapse more likely. Which is precisely why a drug that produces 18–20% weight loss became an interesting proposition for a condition previously treated only with a machine, a mouthguard, or surgery.

It tested tirzepatide against placebo in adults with moderate-to-severe OSA and obesity, over 52 weeks, in two parallel trials split by whether participants used CPAP. That two-trial design was deliberate and important. Trial 1 enrolled people not using positive airway pressure therapy — either because they couldn't tolerate it or had chosen not to. Trial 2 enrolled people already using PAP and continuing it throughout. Running both answers two different clinical questions: can this replace CPAP for people who won't use it, and can it add benefit for people who do?

Participants received the maximum tolerated dose of tirzepatide — 10 mg or 15 mg weekly — or placebo, with AHI measured by overnight polysomnography at baseline and at week 52. The results were published in the New England Journal of Medicine on 21 June 2024.

The headline numbers were large. In Trial 1, mean AHI fell by 27.4 events per hour on tirzepatide versus 4.8 on placebo. In Trial 2, it fell by 29.3 events per hour versus 5.5 on placebo. For context, a participant entering with severe OSA at 50 events per hour and dropping 29 lands in the mild range — a category change, not an incremental improvement.

Weight loss over the same period was approximately 18.1% in Trial 1 and 20.1% in Trial 2, consistent with what tirzepatide produced in the broader SURMOUNT programme. And up to 51.5% of participants met criteria for disease resolution or a downgrade to mild disease, meaning roughly half no longer had the condition they enrolled with.

Secondary outcomes moved in the same direction: systolic blood pressure, hypoxic burden (a measure of how much oxygen desaturation you accumulate overnight), and high-sensitivity C-reactive protein, a marker of systemic inflammation, all improved significantly.

Not on your own, and not without a repeat sleep study. This is the most important practical caveat in an otherwise encouraging story.

Start with what the trial showed. Roughly half of participants met criteria for resolution or mild disease — which means roughly half did not. Response varied considerably between individuals, and there is no reliable way to predict in advance which group you'll fall into. Someone entering at an AHI of 70 and improving by 29 events per hour is still at 41, firmly in severe territory and still needing treatment.

CPAP also remains the most effective treatment for OSA that exists. It works immediately, it works completely when used properly, and its benefits are established over decades. Tirzepatide's effect depends on sustained weight loss, which depends on staying on the medication — and weight regain after stopping GLP-1s is well documented across the trial programme. Your airway follows your weight in both directions.

The correct sequence is straightforward: stay on your current treatment, lose the weight, then get a repeat sleep study. If your AHI has fallen enough, your sleep physician may reduce your pressure settings or, in some cases, discontinue PAP. That's a decision made with objective data, not with the bathroom scale.

One genuinely useful finding from Trial 2 deserves emphasis: people already using CPAP still improved substantially. The two treatments aren't in competition. Many people find lower pressures more comfortable after weight loss, and better tolerance means better adherence — which is the perennial problem with CPAP in the first place.

Because the diagnostic picture that clinicians were trained on was built almost entirely from men. The stereotype — a middle-aged man, loud snoring, witnessed breathing pauses, daytime sleepiness — describes a real presentation that simply isn't how OSA usually shows up in women.

Women more often present with insomnia, fatigue rather than frank sleepiness, morning headaches, low mood, and anxiety. Snoring is frequently absent or minimal, and there may be no partner to witness anything. The result is predictable: a woman describing fatigue, poor sleep, and low mood at 52 gets assessed for depression, or told it's menopause, while the airway is never considered.

And the menopause attribution is doubly unhelpful, because menopause itself sharply increases OSA risk. Prevalence rises substantially after the transition, driven by loss of the protective effect of progesterone on upper airway muscle tone, redistribution of fat toward the neck and trunk, and changes in respiratory control. Postmenopausal women approach male prevalence rates. This is the diagnostic gap covered in [menopause and sleep apnea: the diagnosis women miss](/blog/menopause-sleep-apnea-the-diagnosis-women-miss).

The symptom overlap is close to total. Night sweats fragment sleep; so does apnea. Menopause causes fatigue and brain fog; so does apnea. Both peak in the same decade. A woman can spend years managing what she believes are vasomotor symptoms while an untreated airway condition drives half of it — which is worth considering if you're already working through [sleep on a GLP-1 during menopause](/blog/sleep-on-glp1-during-menopause-night-sweats-and-nausea) and still not waking rested.

If you have unrefreshing sleep, morning headaches, or fatigue that doesn't match your sleep hours, ask specifically about a sleep study. Home sleep apnea testing is now widely available and far less burdensome than an overnight lab visit.

It marks a shift in what these medications are understood to be. SURMOUNT-OSA led the FDA to approve tirzepatide (marketed as Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved for the condition. For patients, that approval has a very practical consequence: an on-label indication makes insurance coverage substantially easier to obtain than a weight-loss-only prescription, where denials remain common. If you've been through that process, [appealing a GLP-1 insurance denial](/blog/glp1-insurance-denial-how-to-appeal-prior-authorization-2026) covers the mechanics.

More broadly, OSA joins a growing list of conditions where GLP-1 medications have shown benefit in dedicated trials rather than as a by-product of weight loss: cardiovascular events in SELECT, kidney outcomes in FLOW, knee osteoarthritis pain in [STEP 9](/blog/glp1-knee-osteoarthritis-step-9-trial-results), and liver fibrosis in [ESSENCE](/blog/glp1-fatty-liver-mash-essence-trial-results). Each of these was a condition previously treated symptomatically, downstream of a metabolic driver nobody could shift.

The pattern is worth naming clearly. These trials are gradually reframing obesity from a cosmetic or willpower issue into a treatable metabolic condition with a long list of downstream diseases — and demonstrating that treating it upstream resolves things further down. Sleep apnea is a particularly clean example, because the causal chain is mechanically obvious: less tissue around the airway, less collapse, fewer events.

What SURMOUNT-OSA does not do is make tirzepatide a sleep medication. It works because it produces weight loss, and it works to the degree that weight loss is achieved and maintained. That's still a meaningful thing for a drug to do — and for the roughly half of participants who left the trial without moderate-to-severe OSA, it was a very meaningful thing indeed.